Immune checkpoints: A therapeutic target in triple negative breast cancer
Early clinical trials investigating monoclonal antibodies targeting the T-cell inhibitory receptor programmed cell death 1 (PD-1) and its ligand PD-L1 have shown efficacy in melanoma, non-small cell lung cancer and renal cell carcinoma. We recently demonstrated PD-L1 expression in 20% of triple nega...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022604/ |